Popular Articles

Clinical Data, Inc. Expands FAMILION(R) Long QT Syndrome Test By Doubling The Number Of Genes
PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), a biotechnology company developing targeted therapeutics and genetic and pharmacogenomic tests to detect diseases and predict drug safety, tolerability and efficacy, announced at the Heart Rhythm Society meeting that it will double the number of genes in its FAMILION Long QT Syndrome (LQTS) Test. By detecting genetic mutations in individuals and their families, the FAMILION LQTS Test can help guide treatment to prevent possible sudden cardiac death. This newly enhanced LQTS Test follows the 3-gene expansion of the FAMILION Hypertrophic Cardiomyopathy (HCM) Test released earlier this year and demonstrates the Company"s leadership in genetic testing for inherited cardiac disorders.
generic viagra
Sub-Optimal Treatment Threatening Survival Of HIV/AIDS Patients
Stagnation in HIV/AIDS funding and the high cost of new medicines are putting the lives of thousands of poor patients at risk, the international medical humanitarian organization Doctors Without Borders/Mç©decins Sans Frontiç¨res (MSF) warned today at the 2009 International AIDS Society conference in South Africa . Patients needing new drug regimens will return to AIDS "death row." While the lack of access to antiretroviral treatment for seven million people remains unaddressed, inadequate financing now further threatens treatment scale-up.
News of the day
Doctors And Software Engineers Pioneer An Advanced Sepsis Detection And Management System
When Jason Martin gives a talk about his research, he begins with the dramatic story of Mariana Bridi da Costa: The young Brazilian supermodel died from severe sepsis in January after amputation of both her hands and feet failed to stop its spread.
Public Health

New Way To Enhance Stem Cells To Stimulate Muscle Regeneration Discovered By Ottawa Scientists

Scientists at the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have discovered a powerful new way to stimulate muscle regeneration, paving the way for new treatments for debilitating conditions such as muscular dystrophy. The research, to be published in the June 5 issue of Cell Stem Cell, shows for the first time that a protein called Wnt7a increases the number of stem cells in muscle tissue, leading to accelerated growth and repair of skeletal muscle. "This discovery shows us that by targeting stem cells to boost their numbers, we can improve the body"s ability to repair muscle tissue," said senior author Dr. Michael Rudnicki. Dr. Rudnicki is the Scientific Director of Canada"s Stem Cell Network and a Senior Scientist at OHRI and Director of OHRI"s Sprott Centre for Stem Cell Research, as well as a Professor of Medicine at the University of Ottawa. Stem cells give rise to every tissue and organ in the body. Satellite stem cells are specialized muscle stem cells that live in adult skeletal muscle tissue and have the ability to both replicate and differentiate into various types of muscle cells. Dr. Rudnicki"s team found that the Wnt7a protein, when introduced into mouse muscle tissue, significantly increased the population of these satellite stem cells and fueled the regeneration process, creating bigger and stronger muscles. Muscle tissue mass was increased by nearly 20 per cent in the study. "Our findings point the way to the development of new therapeutic treatment for muscular diseases such as muscular dystrophy, sarcopenia and muscle wasting conditions resulting from extended hospital stays and surgeries," said Dr. Rudnicki. This project was funded by the Canadian Institutes of Health Research, the Muscular Dystrophy Association, the National Institutes of Health, the Howard Hughes Medical Institute, Canada"s Stem Cell Network and the Canada Research Chairs Program. Jennifer Paterson Ottawa Hospital Research Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):